Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Harvard Business School

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR GLPG2737


✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for GLPG2737

Trial ID Title Status Sponsor Phase Summary
NCT03128606 ↗ A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. Completed Galapagos NV Phase 1 The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737 given for 14 days in healthy women of non-childbearing potential. The purpose of the study is to evaluate the safety and tolerability of single ascending oral doses and multiple ascending oral doses of GLPG3067 given to healthy women of non-childbearing potential compared to placebo, as well as of multiple oral doses of the combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for each compound.
NCT03410979 ↗ A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects Completed Galapagos NV Phase 1 This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.
NCT03450720 ↗ Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis Completed Galapagos NV Phase 1 This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737.
NCT03474042 ↗ GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis Completed Galapagos NV Phase 2 This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d. for 28 days to adult male and female subjects with a confirmed diagnosis of cystic fibrosis homozygous for the F508del CFTR mutation and on stable treatment with Orkambi.
NCT03540524 ↗ A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. Completed Galapagos NV Phase 1 This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.
NCT04578548 ↗ A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Recruiting Galapagos NV Phase 2 This exploratory, randomized, double-blind, placebo-controlled, multicenter, proof of concept, Phase 2a study will evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of orally administered GLPG2737, for a treatment period of 52 weeks, in participants with rapidly progressing ADPKD.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for GLPG2737

Condition Name

Condition Name for
Intervention Trials
Cystic Fibrosis 3
Healthy 2
Autosomal Dominant Polycystic Kidney Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Fibrosis 3
Cystic Fibrosis 3
Kidney Diseases 1
Arthrogryposis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for GLPG2737

Trials by Country

Trials by Country for
Location Trials
Belgium 4
Netherlands 3
Germany 3
Czechia 1
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for GLPG2737

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 2
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GLPG2737

Sponsor Name

Sponsor Name for
Sponsor Trials
Galapagos NV 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Colorcon
Harvard Business School
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.